Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$234.2MCash, Jun 2026
36moCash Runway (est.)
+52%Share Count, 1 Year
Follow LXEO by emailGet an email when LXEO pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about LXEO, unsubscribe in one click. Privacy
📣 What LXEO Says Is Next
second half of 2027 · “The program remains on track to provide a topline data readout in the second half of 2027.”
Company press release, Sep 22, 2026 · SEC filing
early 2027 · “The Company expects to provide a program prioritization update in early 2027 and submit an IND for its next FA development candidate in 2027.”
Company press release, Sep 22, 2026 · SEC filing
Q4 2026 · “Anticipated milestones for the program include: o 12-month data update for all high dose participants in Q4 2026 o Regulatory engagement with the FDA expected in 2026 Pre-Clinical Assets”
Company press release, Aug 12, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
💰 Cash Runway & Dilution Risk
LXEO reported $234.2M in cash and short-term investments (as of Jun 30, 2026) and used about $19.5M/quarter in operations, an estimated runway of 36 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:35 · Moderate
Cash runway 36 months
ATM program on file since Mar 2025 +15
Shelf registration (S-3, Dec 2024) +10
Share count +52% in a year +20
Raised after last reported balance sheet (Sep 2026) -10
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for LXEO and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.